Related Experiment Videos
EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study
1CHU La Grave-Casselardit and INSERM U558, Toulouse, France.
Current Alzheimer Research
|January 13, 2011
Summary
EHT0202 (etazolate hydrochloride) demonstrated good safety and tolerability in mild to moderate Alzheimer's Disease patients. Further studies are needed to confirm its efficacy and long-term safety in a larger patient group.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- EHT0202 (etazolate hydrochloride) is a novel compound for Alzheimer's Disease (AD).
- It targets alpha-secretase activity, GABA-A receptors, and PDE-4.
- Potential disease-modifying and symptomatic treatment properties are being investigated.
Purpose of the Study:
- To assess the clinical safety and tolerability of EHT0202.
- To explore the potential clinical efficacy of EHT0202 as an adjunctive therapy.
- To evaluate EHT0202 in patients with mild to moderate Alzheimer's Disease.
Main Methods:
- A pilot, randomized, double-blind, placebo-controlled, multicentre Phase IIA study.
- 159 patients with mild to moderate AD received EHT0202 (40 or 80 mg bid) or placebo.
- Treatment was adjunctive to acetylcholinesterase inhibitors over 3 months.
Main Results:
- EHT0202 was found to be safe and generally well tolerated.
- Dose-dependent adverse events, including CNS-related events and early withdrawals, were observed.
- No significant differences in efficacy endpoints were noted between groups, except for ADCS-ADL scores.
Conclusions:
- Encouraging safety results support further development of EHT0202.
- Clinical efficacy and long-term tolerability require assessment in larger cohorts.
- EHT0202 shows promise for Alzheimer's Disease treatment.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...